Transplanting Kidney Allografts from Hepatitis C Infected Donors into Hepatitis C Uninfected Recipients: Re-Thinking the Thinker Trial
Read
940
Timeswas read the article
327
Total PDF
613
Total HTML
Share statistics
array:24 [ "pii" => "S1665268119304272" "issn" => "16652681" "doi" => "10.5604/01.3001.0010.2708" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "70249" "copyright" => "Fundación Clínica Médica Sur, A.C." "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2017;16:702-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 73 "formatos" => array:3 [ "EPUB" => 18 "HTML" => 33 "PDF" => 22 ] ] "itemSiguiente" => array:19 [ "pii" => "S1665268119304284" "issn" => "16652681" "doi" => "10.5604/01.3001.0010.2709" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "70250" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2017;16:704-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 166 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 115 "PDF" => 42 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Fibrates for Primary Biliary Cholangitis: What’s All the Hype?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "704" "paginaFinal" => "706" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Cynthia Levy" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Cynthia" "apellidos" => "Levy" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119304284?idApp=UINPBA00004N" "url" => "/16652681/0000001600000005/v1_201905301208/S1665268119304284/v1_201905301208/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1665268119304260" "issn" => "16652681" "doi" => "10.5604/01.3001.0010.2706" "estado" => "S300" "fechaPublicacion" => "2017-09-01" "aid" => "70248" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "edi" "cita" => "Ann Hepatol. 2017;16:699-701" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 68 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 26 "PDF" => 35 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Waiting-Time and Quality of Care Deserved to Patients with Early Stage Hepatocellular Carcinoma Undergoing RFA Treatment" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "699" "paginaFinal" => "701" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Maurizio Soresi, Anna Licata, Lydia Giannitrapani, Giuseppe Montalto" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Maurizio" "apellidos" => "Soresi" ] 1 => array:2 [ "nombre" => "Anna" "apellidos" => "Licata" ] 2 => array:2 [ "nombre" => "Lydia" "apellidos" => "Giannitrapani" ] 3 => array:2 [ "nombre" => "Giuseppe" "apellidos" => "Montalto" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119304260?idApp=UINPBA00004N" "url" => "/16652681/0000001600000005/v1_201905301208/S1665268119304260/v1_201905301208/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "titulo" => "Transplanting Kidney Allografts from Hepatitis C Infected Donors into Hepatitis C Uninfected Recipients: Re-Thinking the Thinker Trial" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "702" "paginaFinal" => "703" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Trana Hussaini, Eric M. Yoshida" "autores" => array:2 [ 0 => array:3 [ "nombre" => "Trana" "apellidos" => "Hussaini" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] ] ] 1 => array:4 [ "nombre" => "Eric M." "apellidos" => "Yoshida" "email" => array:1 [ 0 => "eric.yoshida@vch.ca" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">**</span>" "identificador" => "aff2" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "From the Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada" "etiqueta" => "*" "identificador" => "aff1" ] 1 => array:3 [ "entidad" => "Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada" "etiqueta" => "**" "identificador" => "aff2" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Correspondence and reprint request:" ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="p0010" class="elsevierStylePara elsevierViewall">The Thinker Trial, a small pilot study by Goldberg, <span class="elsevierStyleItalic">et al</span>.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">1</span></a> is a pioneering work, but its application remains firmly rooted in the experimental realm.</p><p id="p0015" class="elsevierStylePara elsevierViewall">The investigators allocated 10 renal allografts from Hepatitis C (HCV) viremic donors to HCV uninfected recipients and promptly treated them with a 12 week regimen of Elbasvir- Grazoprevir. All ten patients achieved sustained virological response (SVR) at 12 weeks and stable renal allograft function. Despite their encouraging results, a few points need to be highlighted. First, the recipients and donors were highly selected as only ten patients of 285 were transplanted. The extensive exclusion criteria ensured only patients without liver pathology or contraindications to liver transplantation were included in this trial. All donors were HCV genotype 1 infected with no baseline NS5A resistance associated substitutions (RAS) ensuring a high SVR rate with 12 weeks of Elbas-vir- Grazoprevir, the direct acting antiviral (DAA) combination rescue therapy. Elbasvir-Grazoprevir is the antiviral of choice in the setting of advanced renal dysfunction, but is only approved for genotype (GT)1 and 4 with an SVR rate of 95% in treatment naïve (TN) individuals.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">2</span></a> We note that the SVR rate in GT1a can be much lower (58%) with the presence of baseline NS5A RAS, hence the utmost attention to rapid genotyping and baseline resistance testing in this trial. Rapid RAS testing of declared donors, however, is currently not available in a community setting. Even in the most favourable scenario of using a TN GT1 infected allograft, there remains a 5% chance of treatment failure with potentially fatal outcomes. Currently, there are limited treatment options for DAA failures and essentially no options if patients have advanced renal disease. In addition, HCV recurrence in the setting of transplantation and heavy immunosuppression can lead to fibrosing cholestat-ic hepatitis (FCH), an aggressive and often fatal hepatitis and, if virologically resistant, a contra-indication to liver transplantation. Although DAAs have dramatically improved the cure rates for HCV, their success is not guaranteed. The risk and consequences of treatment failure might be justifiable in a patient requiring liver transplantation, with the certainty of death in the near future but less defensible in patients with ESRD on renal replacement therapy. Until, we have pangenotypic DAAs effective against resistant variants with a good safety profile in renal dysfunction, and access to rapid genotyping and resistance testing of deceased donors, HCV-infected renal allografts should only be utilized in study settings with patients’ informed consent.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2017-06-15" "fechaAceptado" => "2017-06-15" "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1116233" "palabras" => array:5 [ 0 => "Hepatitis C" 1 => "Transplantation" 2 => "Kidney" 3 => "Allografts" 4 => "Direct acting antiviral agents" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abs0010" class="elsevierStyleSection elsevierViewall"><p id="sp0010" class="elsevierStyleSimplePara elsevierViewall">In the not so distant past, organs from hepatitis C infected donors were either discarded or rarely transplanted into HCV viremic recipients - but never allocated to non-infected patients. However, the simplicity, ease and unprecedented success rates of HCV direct acting antiviral regimens has raised the possibility of utilizing such organs in an attempt to expand the donor pool. The thinker trial reports the first of such attempts. However, caution must be exercised prior to the widespread adoption of such strategy.</p></span>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0010" "bibliografiaReferencia" => array:2 [ 0 => array:3 [ "identificador" => "bib0010" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Goldberg D.S." 1 => "Abt P.L." 2 => "Blumberg E.A." 3 => "Van Deerlin V.M." 4 => "Levine M." 5 => "Reddy K.R." 6 => "Bloom R.D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMc1705221" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2017" "volumen" => "376" "paginaInicial" => "2394" "paginaFinal" => "2395" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28459186" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0015" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Zeuzem S." 1 => "Ghalib R." 2 => "Reddy K.R." 3 => "Pockros P.J." 4 => "Ben Ari Z." 5 => "Zhao Y." 6 => "Brown D.D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7326/M15-0785" "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "2015" "volumen" => "163" "paginaInicial" => "1" "paginaFinal" => "13" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25909356" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/0000001600000005/v1_201905301208/S1665268119304272/v1_201905301208/en/main.assets" "Apartado" => array:4 [ "identificador" => "77921" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Opinions" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/0000001600000005/v1_201905301208/S1665268119304272/v1_201905301208/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119304272?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 2 | 0 | 2 |
| 2024 October | 7 | 4 | 11 |
| 2024 September | 5 | 2 | 7 |
| 2024 August | 8 | 1 | 9 |
| 2024 July | 8 | 2 | 10 |
| 2024 June | 6 | 6 | 12 |
| 2024 May | 8 | 2 | 10 |
| 2024 April | 9 | 9 | 18 |
| 2024 March | 9 | 5 | 14 |
| 2024 February | 4 | 3 | 7 |
| 2024 January | 6 | 3 | 9 |
| 2023 December | 3 | 4 | 7 |
| 2023 November | 3 | 3 | 6 |
| 2023 October | 7 | 3 | 10 |
| 2023 September | 6 | 3 | 9 |
| 2023 August | 7 | 1 | 8 |
| 2023 July | 4 | 2 | 6 |
| 2023 June | 14 | 5 | 19 |
| 2023 May | 36 | 3 | 39 |
| 2023 April | 38 | 1 | 39 |
| 2023 March | 10 | 0 | 10 |
| 2023 February | 14 | 3 | 17 |
| 2023 January | 11 | 2 | 13 |
| 2022 December | 12 | 4 | 16 |
| 2022 November | 34 | 11 | 45 |
| 2022 October | 17 | 6 | 23 |
| 2022 September | 13 | 10 | 23 |
| 2022 August | 9 | 7 | 16 |
| 2022 July | 8 | 6 | 14 |
| 2022 June | 10 | 11 | 21 |
| 2022 May | 7 | 7 | 14 |
| 2022 April | 6 | 9 | 15 |
| 2022 March | 9 | 11 | 20 |
| 2022 February | 6 | 5 | 11 |
| 2022 January | 12 | 7 | 19 |
| 2021 December | 8 | 9 | 17 |
| 2021 November | 8 | 10 | 18 |
| 2021 October | 12 | 6 | 18 |
| 2021 September | 11 | 9 | 20 |
| 2021 August | 20 | 4 | 24 |
| 2021 July | 11 | 8 | 19 |
| 2021 June | 23 | 9 | 32 |
| 2021 May | 20 | 7 | 27 |
| 2021 April | 44 | 19 | 63 |
| 2021 March | 6 | 6 | 12 |
| 2021 February | 3 | 5 | 8 |
| 2021 January | 5 | 5 | 10 |
| 2020 December | 5 | 7 | 12 |
| 2020 November | 5 | 3 | 8 |
| 2020 October | 4 | 3 | 7 |
| 2020 September | 6 | 7 | 13 |
| 2020 August | 4 | 8 | 12 |
| 2020 July | 5 | 9 | 14 |
| 2020 June | 3 | 2 | 5 |
| 2020 May | 2 | 5 | 7 |
| 2020 April | 2 | 0 | 2 |
| 2020 March | 5 | 2 | 7 |
| 2020 February | 3 | 1 | 4 |
| 2020 January | 3 | 3 | 6 |
| 2019 December | 6 | 5 | 11 |
| 2019 November | 3 | 1 | 4 |
| 2019 October | 2 | 1 | 3 |
| 2019 September | 2 | 1 | 3 |
| 2019 August | 0 | 1 | 1 |
| 2019 July | 4 | 3 | 7 |
| 2019 June | 8 | 1 | 9 |
| 2019 May | 2 | 6 | 8 |
Show all
